Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials

Recent studies highlighted genetic aberrations associated with prognosis in Mantle Cell lymphoma (MCL), yet comprehensive testing is not implemented in clinical routine. We conducted a comprehensive genomic characterization of 180 patients from the European MCL network trials by targeted sequencing of peripheral blood DNA using the EuroClonality(EC)-NDC assay. The IGH::CCND1 fusion was identified in 94% of patients, clonal IGH-V-(D)-J rearrangements in all, and 79% had ≥1 somatic gene mutation. The top mutated genes were ATM, TP53, KMT2D, SAMHD1, BIRC3 and NFKBIE. Copy number variations (CNVs) were detected in 83% of patients with RB1, ATM, CDKN2A/B and TP53 being the most frequently deleted and KLF2, CXCR4, CCND1, MAP2K1 and MYC the top amplified genes. CNVs and mutations were more frequently observed in older patients with adverse impact on prognosis. TP53<sup>mut</sup>, NOTCH1<sup>mut</sup>, FAT1<sup>mut</sup> TRAF2<sup>del</sup>, CDKN2A/B<sup>del</sup> and MAP2K1<sup>amp</sup> were linked to inferior failure-free (FFS) and overall survival (OS), while TRAF2<sup>mut</sup>, EGR2<sup>del</sup> and BCL2<sup>amp</sup> related to inferior OS only. Genetic complexity (≥3 CNVs) observed in 51% of analysed patients was significantly associated with impaired FFS and OS. We demonstrate that targeted sequencing from peripheral blood and bone marrow reliably detects diagnostically and prognostically important genetic factors in MCL patients, facilitating genetic characterization in clinical routine.

Authors

Institutions

Publication Details

Journal
Leukemia
Published
2024-09-16
DOI
https://doi.org/10.1038/s41375-024-02375-8
Citations
16
Primary Topic
Lymphoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
6.80
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials

Eva Hoster, Binaya Regmi, Hanneke C. Kluin‐Nelemans, Nikos Darzentas et al.
16 citations
Leukemia
Lymphoma Diagnosis and Treatment
6.80
article

Comprehensive genetic analysis by targeted sequencing identifies risk factors and predicts patient outcome in Mantle Cell Lymphoma: results from the EU-MCL network trials

Eva Hoster, Binaya Regmi, Hanneke C. Kluin‐Nelemans, Nikos Darzentas, Martin Dreyling, Linmiao Jiang, Mouhamad Khouja, Olivier Hermine, Stefan Alig, Martin Schwarz, Karol Pál, Wolfram Klapper, David González de Castro, Peter J. Stewart, Christiane Pott
article en
16 citations

Abstract

Recent studies highlighted genetic aberrations associated with prognosis in Mantle Cell lymphoma (MCL), yet comprehensive testing is not implemented in clinical routine. We conducted a comprehensive genomic characterization of 180 patients from the European MCL network trials by targeted sequencing of peripheral blood DNA using the EuroClonality(EC)-NDC assay. The IGH::CCND1 fusion was identified in 94% of patients, clonal IGH-V-(D)-J rearrangements in all, and 79% had ≥1 somatic gene mutation. The top mutated genes were ATM, TP53, KMT2D, SAMHD1, BIRC3 and NFKBIE. Copy number variations (CNVs) were detected in 83% of patients with RB1, ATM, CDKN2A/B and TP53 being the most frequently deleted and KLF2, CXCR4, CCND1, MAP2K1 and MYC the top amplified genes. CNVs and mutations were more frequently observed in older patients with adverse impact on prognosis. TP53<sup>mut</sup>, NOTCH1<sup>mut</sup>, FAT1<sup>mut</sup> TRAF2<sup>del</sup>, CDKN2A/B<sup>del</sup> and MAP2K1<sup>amp</sup> were linked to inferior failure-free (FFS) and overall survival (OS), while TRAF2<sup>mut</sup>, EGR2<sup>del</sup> and BCL2<sup>amp</sup> related to inferior OS only. Genetic complexity (≥3 CNVs) observed in 51% of analysed patients was significantly associated with impaired FFS and OS. We demonstrate that targeted sequencing from peripheral blood and bone marrow reliably detects diagnostically and prognostically important genetic factors in MCL patients, facilitating genetic characterization in clinical routine.

LeukemiaVol. 38(12)
Queen's University Belfast (GB), Hôpital Necker-Enfants Malades (FR), Centre National de la Recherche Scientifique (FR), Central European Institute of Technology (CZ), University Medical Center Groningen (NL), Inserm (FR), University of Groningen (NL), Université Paris Cité (FR), Sorbonne Université (FR), Central European Institute of Technology – Masaryk University (CZ), Sorbonne Paris Cité (FR), Assistance Publique – Hôpitaux de Paris (FR), Zimmer Biomet (Germany) (DE), University Hospital Schleswig-Holstein (DE), Institut des Maladies Génétiques Imagine (FR), Ludwig-Maximilians-Universität München (DE), RWTH Aachen University (DE), University of Lübeck (DE)
Good health and well-being
Openalex Percentile: Top 3%
Lymphoma Diagnosis and Treatment
6.80
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.